NextGen Jane
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Total Raised
$14.34MInvestors Count
16NextGen Jane Funding, NextGen Jane Valuation & NextGen Jane Revenue
5 Fundings
NextGen Jane's latest funding round was a Debt for $1.5M on June 10, 2022.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
6/10/2022 | Debt | $1.5M | Undisclosed Investors | 1 | ||
2/23/2022 | Grant | |||||
4/1/2019 | Series A | |||||
3/10/2016 | Seed | |||||
12/9/2015 | Convertible Note |
Date | 6/10/2022 | 2/23/2022 | 4/1/2019 | 3/10/2016 | 12/9/2015 |
|---|---|---|---|---|---|
Round | Debt | Grant | Series A | Seed | Convertible Note |
Amount | $1.5M | ||||
Investors | Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 1 |
NextGen Jane Investors
16 Investors
NextGen Jane has 16 investors. National Institutes of Health invested in NextGen Jane's Grant funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
2/23/2022 | 2/23/2022 | 1 Grant | Government | Maryland | ||
4/1/2019 | 4/1/2019 | 1 Series A | Angel Investor (Individual) | United States | ||
4/1/2019 | 4/1/2019 | 1 Series A | Angel Investor (Individual) | |||
Angel Investor (Individual) | ||||||
Angel Investor (Individual) |
First funding | 2/23/2022 | 4/1/2019 | 4/1/2019 | ||
|---|---|---|---|---|---|
Last Funding | 2/23/2022 | 4/1/2019 | 4/1/2019 | ||
Investor | |||||
Rounds | 1 Grant | 1 Series A | 1 Series A | ||
Board Seats | |||||
Type | Government | Angel Investor (Individual) | Angel Investor (Individual) | Angel Investor (Individual) | Angel Investor (Individual) |
Location | Maryland | United States |
You May Also Like
Temple Therapeutics is a pharmaceutical clinical development company with a global footprint, focused on diseases where abnormal tissue growth and dysfunction are common hallmarks and lead to fibrosis, pain, infertility, and cancers. The company was founded in 2020 and is based in Geleen, Netherlands.
DotLab is developing a non-invasive test for endometriosis.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.